Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Phase 2
90
about 5.3 years
21–70
1 site in MD
About this study
This trial is testing whether psilocybin can help people with opioid use disorder (OUD) stay sober and improve their lives when used alongside buprenorphine treatment. Participants will receive either a high dose or a low dose of psilocybin as an addition to standard outpatient buprenorphine care, and it will last for 1939 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Psilocybin
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
oral
Secondary: Depression as assessed by the Beck Depression Inventory II (BDII), Quality of Life as assessed by the World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Psychiatry / Mental Health